A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad

Brief description of study

If you have been diagnosed with advanced malignancies, an advanced form of cancer, you may be qualified to participate in this Phase I study evaluating the drug REGN3767 alone or in combination with REGN2810. The goal of this study is to determine if the experimental drug REGN3767 is safe and tolerable alone or in combination with REGN2810 in treating patients who have advanced malignancies.


Clinical Study Identifier: s17-00257
ClinicalTrials.gov Identifier: NCT03005782
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.